Lorvotuzumab mertansine: Antibody-drug-conjugate for CD56+ multiple myeloma

Frontiers in Bioscience - Landmark

Volumn 19, Issue 1, 2014, Pages 163-170

  Berdeja, Jesus G ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Antibody drug conjugate; CD56; DM1; Lorvotuzumab mertansine; Multiple myeloma; Review

Indexed keywords

ANTIBODY CONJUGATE; CD56 ANTIGEN; DRUG DERIVATIVE; LORVOTUZUMAB MERTANSINE; MAYTANSINE; MONOCLONAL ANTIBODY;

ARTICLE; HUMAN; IMMUNOLOGY; MULTIPLE MYELOMA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD56; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MULTIPLE MYELOMA;

EID: 84902357463     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4202     Document Type: Article

References (31)

1. N. A. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). In: National Cancer Institute. Eds: N. Howlader, M. Krapcho, N. Neyman, R. Aminou, SF Altekruse, CL Kosary, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, M.P. Eisner, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin KA Bethesda, MD (2012)
2. T. Plesner, H. Lokhorst, P. Gimsing, H. Nahi, S. Lisby and P. G. Richardson: Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. ASH Annual Meeting Abstracts, 120(21), 73- (2012)
3. J. Endell, R. Boxhammer, C. Wurzenberger, D. Ness and S. Steidl: The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo. ASH Annual Meeting Abstracts, 120(21), 4018- (2012)
4. P. Neri, S. Kumar, M. Fulciniti, S. Vallet, S. Chhetri, H. Yasui, Y.-T. Tai, D. Chauhan, T. Hideshima, P. Tassone, S. Venuta, N. C. Munshi, K. C. Anderson and N. Raje: The In Vivo Activity of Neutralizing B Cell-Activating Factor (BAFF) Antibody in the Treatment of Multiple Myeloma (MM). ASH Annual Meeting Abstracts, 108(11), 843- (2006)
5. N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, H. Yasui, Y.-T. Tai, N. Shiraishi, T. Kizeltepe, S. Chhetri, S. Vallet, R. L. Schlossman, P. G. Richardson, N. C. Munshi and K. C. Anderson: The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM). ASH Annual Meeting Abstracts, 106(11), 3380- (2005)
6. M. S. Kaminski, K. R. Zasadny, I. R. Francis, M. C. Fenner, C. W. Ross, A. W. Milik, J. Estes, M. Tuck, D. Regan, S. Fisher, S. D. Glenn and R. L. Wahl: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol, 14(7), 1974-81 (1996)
7. T. E. Witzig, C. A. White, G. A. Wiseman, L. I. Gordon, C. Emmanouilides, A. Raubitschek, N. Janakiraman, J. Gutheil, R. J. Schilder, S. Spies, D. H. Silverman, E. Parker and A. J. Grillo-Lopez: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol, 17(12), 3793-803 (1999)
8. E. L. Sievers, R. A. Larson, E. A. Stadtmauer, E. Estey, B. Lowenberg, H. Dombret, C. Karanes, M. Theobald, J. M. Bennett, M. L. Sherman, M. S. Berger, C. B. Eten, M. R. Loken, J. J. van Dongen, I. D. Bernstein and F. R. Appelbaum: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol, 19(13), 3244-54 (2001)
9. P. F. Bross, J. Beitz, G. Chen, X. H. Chen, E. Duffy, L. Kieffer, S. Roy, R. Sridhara, A. Rahman, G. Williams and R. Pazdur: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res, 7(6), 1490-6 (2001)
10. R. V. Chari, B. A. Martell, J. L. Gross, S. B. Cook, S. A. Shah, W. A. Blattler, S. J. McKenzie and V. S. Goldmacher: Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res, 52(1), 127-31 (1992)
11. L. L. Lanier, R. Testi, J. Bindl and J. H. Phillips: Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med, 169(6), 2233-8 (1989)
12. K. Patel, S. E. Moore, G. Dickson, R. J. Rossell, P. C. Beverley, J. T. Kemshead and F. S. Walsh: Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma. Int J Cancer, 44(4), 573-8 (1989)
13. B. Van Camp, B. G. Durie, C. Spier, M. De Waele, I. Van Riet, E. Vela, Y. Frutiger, L. Richter and T. M. Grogan: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood, 76(2), 377-82 (1990)
14. H. Harada, M. M. Kawano, N. Huang, Y. Harada, K. Iwato, O. Tanabe, H. Tanaka, A. Sakai, H. Asaoku and A. Kuramoto: Phenotypic difference of normal plasma cells from mature myeloma cells. Blood, 81(10), 2658-63 (1993)
15. P. Tassone, A. Gozzini, V. Goldmacher, M. A. Shammas, K. R. Whiteman, D. R. Carrasco, C. Li, C. K. Allam, S. Venuta, K. C. Anderson and N. C. Munshi: In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Research, 64(13), 4629-4636 (2004)
16. N. Sahara, A. Takeshita, K. Shigeno, S. Fujisawa, K. Takeshita, K. Naito, M. Ihara, T. Ono, S. Tamashima, K. Nara, K. Ohnishi and R. Ohno: Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol, 117(4), 882-5 (2002)
17. S. Remillard, L. I. Rebhun, G. A. Howie and S. M. Kupchan: Antimitotic activity of the potent tumor inhibitor maytansine. Science, 189(4207), 1002-5 (1975)
18. R. Lutz, O. Ab, K. Foley, V. Goldmacher, K. Whiteman, H. Xie and R. Fram: Efficacy of the huN901-DM1 conjugate in combination with antineoplastic agents against multiple myeloma cells in preclinical studies. AACR Meeting Abstracts, 2007(1-Annual-Meeting), 5577- (2007)
19. K. Whiteman, O. Ab, L. Bartle, K. Foley, V. Goldmacher and R. Lutz: Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies. AACR Meeting Abstracts, 2008(1-Annual-Meeting), 2146- (2008)
20. K. Whiteman, H. Johnson, S. Xu, J. Moreland, V. Vyas, L. Bartle, O. Ab, C. Carrigan, J. Pinkas and R. Lutz: Abstract #2799: Combination therapy with IMGN901 and lenalidomide plus low-dose dexamethasone is highly effective in multiple myeloma xenograft models. AACR Meeting Abstracts, 2009(2-Annual- Meeting), 2799- (2009)
21. A. Chanan-Khan, J. Wolf, M. Gharibo, S. Jagannath, N. C. Munshi, K. C. Anderson, D. Manfredi, K. P. Lee, K. C. Miller, R. Guild, S. Zildjian, A. Qin, J. O'Leary and R. Vescio: Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis. ASH Annual Meeting Abstracts, 114(22), 2883- (2009)
22. A. Chanan-Khan, J. L. Wolf, J. Garcia, M. Gharibo, S. Jagannath, D. Manfredi, T. Sher, C. Martin, S. H. Zildjian, J. O'Leary and R. Vescio: Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis. ASH Annual Meeting Abstracts, 116(21), 1962- (2010)
23. J. Blade, D. Samson, D. Reece, J. Apperley, B. Bjorkstrand, G. Gahrton, M. Gertz, S. Giralt, S. Jagannath and D. Vesole: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 102(5), 1115-23 (1998)
24. J. G. Berdeja, S. Ailawadhi, S. Weitman, S. Zildjian, J. O'Leary, J. O'Keeffe, R. Guild, K. R. Whiteman and A. A. Chanan-Khan: Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma. J Clin Oncol, 29(suppl) (2011)
25. J. G. Berdeja, F. Hernandez-Ilizaliturri, A. Chanan-Khan, M. Patel, K. R. Kelly, K. L. Running, M. Murphy, R. Guild, C. Carrigan, S. Ladd, B. B. Wolf, J. J. O'Leary and S. Ailawadhi: Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM). ASH Annual Meeting Abstracts, 120(21), 728- (2012)
26. P. J. Woll, K. N. Moore, S. Bhatia, F. V. Fossella, L. C. Chen, M. O'Brien, P. Lorigan, S. Weitman, J. O'Leary, S. Zildjian, E. Bulger, R. Guild and M. H. Shah: Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. J Clin Oncol, 29(suppl) (2011)
27. H. Erickson, M. Mayo, W. Widdison, C. Audette, Y. Kovtun, R. Chari, R. Lutz and R. Singh: Linker selection in antibody-maytansinoid conjugates impacts bystander killing in mouse xenograft models. AACR Meeting Abstracts, 2007(3-Molecular-Targets-Meeting), A86- (2007)
28. R. J. Lutz and K. R. Whiteman: Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs, 1(6), 548-51 (2009)
29. J. Q. Rose, A. M. Yurchak, A. W. Meikle and W. J. Jusko: Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. J Pharmacokinet Biopharm, 9(1), 1-14 (1981)
30. B. T. O'Sullivan, D. J. Cutler, G. E. Hunt, C. Walters, G. F. Johnson and I. D. Caterson: Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol Psychiatry, 41(5), 574-84 (1997)
31. D. B. Rosen, K. H. Harrington, J. A. Cordeiro, L. Y. Leung, S. Putta, N. Lacayo, G. S. Laszlo, C. J. Gudgeon, D. E. Hogge, R. E. Hawtin, A. Cesano and R. B. Walter: AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One, 8(1), e53518 (2013)